The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

EPB42  -  erythrocyte membrane protein band 4.2

Homo sapiens

Synonyms: E42P, Erythrocyte membrane protein band 4.2, Erythrocyte protein 4.2, MGC116735, MGC116737, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of EPB42


High impact information on EPB42


Chemical compound and disease context of EPB42

  • Imipenem resistant PA bacteraemia were associated with higher incidence of septic shock (40% vs 19.8%, p < 0.02) and death (33.3%) than ISPA bacteraemias [7].
  • Five factors were associated with a decrement in CrCl greater than the average decrease (17.6%): presence of hydronephrosis, age <50, no history of cisplatin treatment, a BED to gross adenopathy exceeding mean BED, and salvage treatment of PA node recurrence [8].

Biological context of EPB42

  • Hence, the genes for B3, P4.2, and beta-spectrin (beta-SP) appear to be suitable models to study the relationship between methylation of promoter 5'-CG-3' sites and the sequential expression of genes during human erythroid development and differentiation [9].
  • The octyl-beta-glucoside ghost extracts from both P4.2-deficient phenotypes were enriched in band 3 oligomeric species (tetramers, higher-order oligomers, and aggregates) compared with controls [6].
  • The molecular basis of Japanese P4.2-deficiency was investigated by reverse transcription of total reticulocyte RNA, followed by polymerase chain reaction (PCR) amplification, subcloning, and sequencing [10].
  • The complete cDNA sequence of a P4.2-deficient patient showed a single point mutation that changes codon 142 from GCT (alanine) to ACT (threonine) (Protein 4.2NIPPON) [10].
  • The major membrane binding site for P4.2 is contained within the cytoplasmic domain of band 3 (cdb3), although the precise location of the cdb3 binding site is not known [11].

Anatomical context of EPB42


Associations of EPB42 with chemical compounds

  • Molecular cloning of P4.2 cDNAs showed that P4.2 is a transglutaminaselike molecule in erythrocytes but lacks the essential cysteine for cross-linking activity [16].
  • Human erythrocyte membrane protein band 4.2 (pallidin) [17].
  • Control cells uniformly secreted PAI activity (70.3 +/- 24.9 PAI U/ml), while calcitriol pretreatment induced the cells to secrete PA activity (52.6 +/- 47.2 milli-Ploug unit/ml) [14].
  • Eight patients receiving an oral glucose load before surgery demonstrated a significant greater relative increase in IGFBP-3-PA compared with 10 patients not receiving glucose (32.9 +/- 7.1% vs. 8.6 +/- 6.7%, respectively; P < 0.05) [4].
  • Nevertheless, u-PA mRNA level in EGF-, TGFbeta1 - or DHT-treated cells was amplified only between 110 and 180% of control, suggesting that growth factors differently controlled the steps of PA expression [5].

Other interactions of EPB42


Analytical, diagnostic and therapeutic context of EPB42

  • Micro-aggregation (PA) and macro-aggregation (TA) were determined respectively by electronic particle counting and light transmission (turbidimetry) [19].
  • We carried out a cross sectional and longitudinal study to assess whether bioimpedance indexes (resistance, Rz; reactance, Xc; phase angle, PA) reflect the nutritional status of hemodialysis (HD) patients, and bear a significant association with their long-term survival [20].
  • STUDY OBJECTIVES: To compare adherence and clinical outcomes between flexible positive airway pressure (PAP) [C-Flex; Respironics; Murraysville, PA] and standard PAP therapy (ie, continuous positive airway pressure [CPAP]) [21].
  • Among these monoclonal antibodies, only five reacted with PA in A/PR/8/34 virus-infected cells in indirect immunofluorescence assay [22].
  • Twenty-two monoclonal antibodies reacting with PA protein in ELISA were divided into 10 groups on the basis of competitive binding patterns to this protein [22].


  1. The gene for human erythrocyte protein 4.2 maps to chromosome 15q15. Najfeld, V., Ballard, S.G., Menninger, J., Ward, D.C., Bouhassira, E.E., Schwartz, R.S., Nagel, R.L., Rybicki, A.C. Am. J. Hum. Genet. (1992) [Pubmed]
  2. A novel mutation in the erythrocyte protein 4.2 gene of Japanese patients with hereditary spherocytosis (protein 4.2 Fukuoka). Takaoka, Y., Ideguchi, H., Matsuda, M., Sakamoto, N., Takeuchi, T., Fukumaki, Y. Br. J. Haematol. (1994) [Pubmed]
  3. Comparison of amikacin and gentamicin. Klastersky, J., Odio, W., Hensgens, C. Clin. Pharmacol. Ther. (1975) [Pubmed]
  4. Postoperative induction of insulin-like growth factor binding protein-3 proteolytic activity: relation to insulin and insulin sensitivity. Bang, P., Nygren, J., Carlsson-Skwirut, C., Thorell, A., Ljungqvist, O. J. Clin. Endocrinol. Metab. (1998) [Pubmed]
  5. Divergent effect of TGFbeta1 on growth and proteolytic modulation of human prostatic-cancer cell lines. Desruisseau, S., Ghazarossian-Ragni, E., Chinot, O., Martin, P.M. Int. J. Cancer (1996) [Pubmed]
  6. Increased rotational mobility and extractability of band 3 from protein 4.2-deficient erythrocyte membranes: evidence of a role for protein 4.2 in strengthening the band 3-cytoskeleton linkage. Rybicki, A.C., Schwartz, R.S., Hustedt, E.J., Cobb, C.E. Blood (1996) [Pubmed]
  7. Imipenem-resistant Ps. aeruginosa bacteraemia in cancer patients: risk factors, clinical features and outcome. Krcméry, V., Trupl, J., Kunová, A., Spánik, S., Ilavská, I., Hel'pianska, L., Bezáková, I., Drgona, L., Oravcová, E., Studená, M., Lacka, J., Sevcíková, L., Koren, P., Kukucková, E., Stopková, K., Krupová, I., Grausová, S., Svec, J. Bratislavské lekárske listy. (1996) [Pubmed]
  8. The potential nephrotoxic effects of intensity modulated radiotherapy delivered to the para-aortic area of women with gynecologic malignancies: preliminary results. Varlotto, J.M., Gerszten, K., Heron, D.E., Comerci, J., Gautam, S., Selvaraj, R., Lalonde, R., Chura, J.C. Am. J. Clin. Oncol. (2006) [Pubmed]
  9. Relationships between DNA methylation and expression in erythrocyte membrane protein (band 3, protein 4.2, and beta-spectrin) genes during human erythroid development and differentiation. Remus, R., Kanzaki, A., Yawata, A., Wada, H., Nakanishi, H., Sugihara, T., Zeschnigk, M., Zuther, I., Schmitz, B., Naumann, F., Doerfler, W., Yawata, Y. Int. J. Hematol. (2005) [Pubmed]
  10. An alanine-to-threonine substitution in protein 4.2 cDNA is associated with a Japanese form of hereditary hemolytic anemia (protein 4.2NIPPON). Bouhassira, E.E., Schwartz, R.S., Yawata, Y., Ata, K., Kanzaki, A., Qiu, J.J., Nagel, R.L., Rybicki, A.C. Blood (1992) [Pubmed]
  11. Identification of a band-3 binding site near the N-terminus of erythrocyte membrane protein 4.2. Rybicki, A.C., Musto, S., Schwartz, R.S. Biochem. J. (1995) [Pubmed]
  12. Immuno-analogues of erythrocyte protein 4.2 in thyroid gland. Shimizu, T., Takakuwa, Y., Ohkawara, A. Acta Histochem. (1995) [Pubmed]
  13. Regulation of phosphatidic acid phosphohydrolase activity during stimulation of human polymorphonuclear leukocytes. Truett, A.P., Bocckino, S.B., Murray, J.J. FASEB J. (1992) [Pubmed]
  14. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester. Gyetko, M.R., Webb, A.C., Sitrin, R.G. J. Immunol. (1988) [Pubmed]
  15. The effect of variations in dietary fatty acids on the fatty acid composition of erythrocyte phosphatidylcholine and phosphatidylethanolamine in human infants. Putnam, J.C., Carlson, S.E., DeVoe, P.W., Barness, L.A. Am. J. Clin. Nutr. (1982) [Pubmed]
  16. Human erythrocyte protein 4.2: isoform expression, differential splicing, and chromosomal assignment. Sung, L.A., Chien, S., Fan, Y.S., Lin, C.C., Lambert, K., Zhu, L., Lam, J.S., Chang, L.S. Blood (1992) [Pubmed]
  17. Human erythrocyte membrane protein band 4.2 (pallidin). Cohen, C.M., Dotimas, E., Korsgren, C. Semin. Hematol. (1993) [Pubmed]
  18. Recruitment of the SWI/SNF protein Brg1 by a multiprotein complex effects transcriptional repression in murine erythroid progenitors. Xu, Z., Meng, X., Cai, Y., Koury, M.J., Brandt, S.J. Biochem. J. (2006) [Pubmed]
  19. Platelet size affects both micro- and macro-aggregation: contributions of platelet number, volume fraction and cell surface. Wong, T., Pedvis, L., Frojmovic, M. Thromb. Haemost. (1989) [Pubmed]
  20. Nutritional and prognostic correlates of bioimpedance indexes in hemodialysis patients. Maggiore, Q., Nigrelli, S., Ciccarelli, C., Grimaldi, C., Rossi, G.A., Michelassi, C. Kidney Int. (1996) [Pubmed]
  21. Treatment adherence and outcomes in flexible vs standard continuous positive airway pressure therapy. Aloia, M.S., Stanchina, M., Arnedt, J.T., Malhotra, A., Millman, R.P. Chest (2005) [Pubmed]
  22. Epitope mapping of the influenza A virus RNA polymerase PA using monoclonal antibodies. Hatta, M., Asano, Y., Masunaga, K., Ito, T., Okazaki, K., Toyoda, T., Kawaoka, Y., Ishihama, A., Kida, H. Arch. Virol. (2000) [Pubmed]
WikiGenes - Universities